CTLA-4-silencing RNAi agent (Phio Pharmaceuticals)

N/A

Report date: 2025/10/22 15:36:30
NME

Base Information

Drug NameCTLA-4-silencing RNAi agent (Phio Pharmaceuticals)
Drug Alias NameCTLA-4 checkpoint inhibitor (Phio Pharmaceuticals)
ClassificationSmall molecules > Nucleosides and nucleotide derivtives > Oligonucleotide > Small Interfering RNA
Mechanisms of ActionCytotoxic T-Lymphocyte-Associated Antigen 4 inhibitorsRNA interference
TargetsCytotoxic T-Lymphocyte-Associated Antigen 4
Therapy Area/IndicationsColonic NeoplasmsCarcinoma, HepatocellularNeoplasms
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPreclinical
Highest Status in ChinaN/A
Originator CompaniesPhio Pharmaceuticals Corp
China Registration ClassN/A

Develop Information

Active CompaniesPhio Pharmaceuticals Corp
Inactive CompaniesN/A
Active IndicationsColonic NeoplasmsCarcinoma, Hepatocellular
Inactive IndicationsNeoplasms

Other Information

ATC CodeN/A
Related LinksN/A